In active psoriatic arthritisSTELARA® Dosing 4 Your Patients1

In active PsA

  • The recommended dose is 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks1
  • For patients with coexistent moderate to severe plaque psoriasis weighing >220 lbs, the recommended dose is 90 mg initially and 4 weeks later, followed by 90 mg every 12 weeks1

 

STELARA®, available as 45 mg and 90 mg, is a subcutaneous injection intended for use under the guidance and supervision of a physician with patients who will be closely monitored and have regular follow-up. Patients may self-inject with STELARA® after physician approval and proper training. Patients should be instructed to follow the direction provided in the Medication Guide.

STELARA® is available in 2 fixed doses—45 mg and 90 mg1.

 

Fewer Doses than Any Other Biologic Therapy 4 PsA1-5

Dosing of commonly used biologic treatments in PsA— first 24 weeks of therapy

STELARA® (ustekinumab) dosing vs Enbrel® (etanercept), Humira® (adalimumab), Costentyx® (secukinumab), and Otezla® (apremilast)
STELARA®

Once every 12 weeks
(after 2 starter doses at Weeks 0 and 4)1

Just 4 maintenance
doses per year!

STELARA® (ustekinumab) dosing vs Enbrel® (etanercept), Humira® (adalimumab), Costentyx® (secukinumab), and Otezla® (apremilast)
Enbrel®
(etanercept)

Once every week2

STELARA® (ustekinumab) dosing vs Enbrel® (etanercept), Humira® (adalimumab), Costentyx® (secukinumab), and Otezla® (apremilast)
Humira®
(adalimumab)

Once every other week3

STELARA® (ustekinumab) dosing vs Enbrel® (etanercept), Humira® (adalimumab), Costentyx® (secukinumab), and Otezla® (apremilast)
Cosentyx®
(secukinumab)

Once every 4 weeks
(after once-weekly dosing for the first 5 doses)4*

*For psoriatic arthritis patients with coexistent moderate to severe plaque psoriasis, use the dosing and administration recommendations for plaque psoriasis. The recommended dosage is 300 mg by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. Each 300 mg dosage is given as 2 subcutaneous injections of 150 mg. For some patients, a dosage of 150 mg may be acceptable.4 For other psoriatic arthritis patients, administer Cosentyx® with or without a loading dosage by subcutaneous injection. The recommended dosage:

  • With a loading dosage is 150 mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter4
  • Without a loading dosage is 150 mg every 4 weeks4
  • If a patient continues to have active psoriatic arthritis, consider a dosage of 300 mg. Cosentyx® may be administered with or without MTX4

 

Fewer Doses Than Otezla1,5
STELARA® (ustekinumab) dosing vs Enbrel® (etanercept), Humira® (adalimumab),   Costentyx® (secukinumab), and Otezla® (apremilast)
Otezla®
(apremilast)

One dose on Day 1;
twice-daily dosing on
Days 2 to 5, followed
by twice-daily
maintenance dosing5

Fewer Yearly Doses than Any Other Biologic Therapy 4 PsA1-5
Dosing of commonly used biologic treatments in PsA—first 52 weeks of therapy
STELARA® (ustekinumab) dosing vs Enbrel® (etanercept), Costentyx® (secukinumab), Humira® (adalimumab), and Otezla® (apremilast) Year 1
STELARA®

Once every 12 weeks
(after 2 starter doses at Weeks 0 and 4)1

Just 4 maintenance doses per year!

STELARA® (ustekinumab) dosing vs Enbrel® (etanercept), Costentyx® (secukinumab), Humira® (adalimumab), and Otezla® (apremilast) Year 1
Enbrel®
(etanercept)

Once every week2

STELARA® (ustekinumab) dosing vs Enbrel® (etanercept), Costentyx® (secukinumab), Humira® (adalimumab), and Otezla® (apremilast) Year 1
Humira®
(adalimumab)

Once every other week3

STELARA® (ustekinumab) dosing vs Enbrel® (etanercept), Costentyx® (secukinumab), Humira® (adalimumab), and Otezla® (apremilast) Year 1
Cosentyx®
(secukinumab)

Once every 4 weeks
(after once-weekly dosing for the first 5 doses)4*

*For psoriatic arthritis patients with coexistent moderate to severe plaque psoriasis, use the dosing and administration recommendations for plaque psoriasis. The recommended dosage is 300 mg by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. Each 300 mg dosage is given as 2 subcutaneous injections of 150 mg. For some patients, a dosage of 150 mg may be acceptable.4 For other psoriatic arthritis patients, administer Cosentyx® with or without a loading dosage by subcutaneous injection. The recommended dosage:

  • With a loading dosage is 150 mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter4
  • Without a loading dosage is 150 mg every 4 weeks4
  • If a patient continues to have active psoriatic arthritis, consider a dosage of 300 mg. Cosentyx® may be administered with or without MTX4

 

Fewer Yearly Doses than Otezla®1,5
STELARA® (ustekinumab) dosing vs Enbrel® (etanercept), Costentyx® (secukinumab), Humira® (adalimumab), and Otezla® (apremilast) Year 1
Otezla®
(apremilast)

One dose on Day 1;
twice-daily dosing on
Days 2 to 5, followed
by twice-daily maintenance dosing5

This presentation is not intended to compare the relative safety or efficacy of these treatments. Please refer to the Prescribing Information of each agent for dosage and administration. All trademarks are property of their respective owners.

 

References: 1. STELARA [package insert]. Horsham, PA: Janssen Biotech, Inc; 2016. 2. Enbrel [package insert]. Thousand Oaks, CA: Immunex Corp; 2017. 3. Humira [package insert]. North Chicago, IL: AbbVie, Inc; 2017. 4. Cosentyx [package insert]. East Hanover, NJ: Novartis Pharmaceuticals, Corp; 2016. 5. Otezla [package insert]. Summit, NJ: Celgene Corp; 2017.

close tooltip
Enbrel® (etanercept) Indication

Enbrel® is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (PsA). Enbrel® can be used with or without MTX.2

close tooltip
Humira® (adalimumab) Indication

Humira® is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. Humira® can be used alone or in combination with nonbiologic DMARDS.3

close tooltip
Cosentyx® (secukinumab) Indication

Cosentyx® is indicated for the treatment of adult patients with active psoriatic arthritis.4

close tooltip
Otezla® (apremilast) Indication, tablets for oral use

Otezla® is indicated for the treatment of adult patients with active psoriatic arthritis.5

close tooltip
Humira® (adalimumab) Indication

Humira® is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. Humira® can be used alone or in combination with nonbiologic DMARDS.3

close tooltip
Cosentyx® (secukinumab) Indication

Cosentyx® is indicated for the treatment of adult patients with active psoriatic arthritis.4

close tooltip
Otezla® (apremilast) Indication, tablets for oral use

Otezla® is indicated for the treatment of adult patients with active psoriatic arthritis.5

close tooltip
Enbrel®(etanercept) Indication

Enbrel® is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (PsA). Enbrel® can be used with or without MTX.2